International Companies

Merck to buy Cidara Therapeutics in $9.2bn deal, shares rocket

By Michele Maatouk

Date: Friday 14 Nov 2025

(Sharecast News) - Shares in Cidara Therapeutics rocketed on Friday after the biotechnology firm agreed to be taken over by Merck in $9.2bn deal.
Under the terms of the transaction, Merck will pay $221.50 per share in cash.

Cidara's lead candidate, CD388 - a novel long-acting antiviral conjugate - is...

Sign up for free or to read the full story

Email this article to a friend

or share it with one of these popular networks:


Article Archive

Top of Page